As in previous studies, the SHIELD study found health care workers who received the Novavax vaccine reported significantly ...

Novavax, Inc. (Nasdaq: NVAX) today announced preliminary results from the SHIELD-Utah study (Study of Healthcare Workers and ...

Novavax (NasdaqGS:NVAX) recently announced promising preliminary results from the SHIELD-Utah study, which highlighted fewer and less severe reactogenicity symptoms for its COVID-19 Vaccine, ...

Workers who received Novavax reported 12.5% fewer local reactions than those who received the Pfizer vaccine. Average hours ...

Novavax (NVAX) announced preliminary results from the SHIELD-Utah study that showed Novavax’s COVID-19 Vaccine, Adjuvanted 2024-2025 Formula ...

Preliminary data showed Novavax's (NVAX) non-mRNA JN.1 COVID-19 vaccine induced lower frequency and severity of short-term side effects and impact on daily life compared with Pfizer-BioNTech mRNA ...

An advisory panel on vaccines meets, carefully, in the shadow of a health secretary who has often criticized it.

Shares in US biotech Novavax fell more than 20% before the weekend, following remarks from health and human services ...

Complex Pandemic Accord negotiations have been under way since 2021, with 13 formal meetings and numerous informal sessions.

The health secretary has chipped away at the idea that immunizing children against measles and other diseases is a public ...